Literature DB >> 11012550

Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

J F Westphal1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11012550      PMCID： PMC2015000          DOI： 10.1046/j.1365-2125.2000.00261.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  85 in total

1.  The mechanism of cyclosporine toxicity induced by clarithromycin.

Authors:  S T Spicer; C Liddle; J R Chapman; P Barclay; B J Nankivell; P Thomas; P J O'Connell
Journal:  Br J Clin Pharmacol       Date:  1997-02       Impact factor: 4.335

2.  From the Food and Drug Administration.

Authors:  S L Nightingale
Journal:  JAMA       Date:  1992-08-12       Impact factor: 56.272

3.  Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450.

Authors:  T K Chang; F J Gonzalez; D J Waxman
Journal:  Arch Biochem Biophys       Date:  1994-06       Impact factor: 4.013

4.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).

Authors:  Y Tanigawara; N Okamura; M Hirai; M Yasuhara; K Ueda; N Kioka; T Komano; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

5.  A potentially hazardous interaction between erythromycin and midazolam.

Authors:  K T Olkkola; K Aranko; H Luurila; A Hiller; L Saarnivaara; J J Himberg; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

6.  Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.

Authors:  G Engel; U Hofmann; H Heidemann; J Cosme; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1996-06       Impact factor: 6.875

7.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

Authors:  J C Kolars; P Schmiedlin-Ren; J D Schuetz; C Fang; P B Watkins
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

8.  The fate of naringin in humans: a key to grapefruit juice-drug interactions?

Authors:  U Fuhr; A L Kummert
Journal:  Clin Pharmacol Ther       Date:  1995-10       Impact factor: 6.875

Review 9.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

10.  QT interval prolongation and torsades de pointes due to erythromycin lactobionate.

Authors:  K C Oberg; J L Bauman
Journal:  Pharmacotherapy       Date:  1995 Nov-Dec       Impact factor: 4.705
View more
  46 in total

Review 1.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

Review 2.  The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.

Authors:  Abdo Haddad; Mellar Davis; Ruth Lagman
Journal:  Support Care Cancer       Date:  2006-12-01       Impact factor: 3.603

Review 3.  [Cytochrom-P450 mediated drug interactions caused by antibiotics].

Authors:  Christiane Thallinger; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2006-09

4.  PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.

Authors:  Alison E Fohner; Alex Sparreboom; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-04       Impact factor: 2.089

5.  Macrolide-theophylline interactions: no role for the inhibition of cytochrome P4501A2.

Authors:  Thomas M Polasek; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

6.  Rhabdomyolysis following a short course of clarythromycin.

Authors:  Anna M Schor; Ann Hellerstein
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

Review 7.  Efficacy and safety of long-term antibiotics (macrolides) for the treatment of chronic rhinosinusitis.

Authors:  Anders Cervin; Ben Wallwork
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

Review 8.  Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials.

Authors:  Charles Feldman; Ronald Anderson
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

9.  Identification of severe potential drug-drug interactions using an Italian general-practitioner database.

Authors:  L Magro; A Conforti; F Del Zotti; R Leone; M L Iorio; I Meneghelli; D Massignani; E Visonà; U Moretti
Journal:  Eur J Clin Pharmacol       Date:  2007-11-09       Impact factor: 2.953

10.  Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.

Authors:  Rocco Orlando; Pierpaolo Piccoli; Sara De Martin; Roberto Padrini; Pietro Palatini
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.